Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.

Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.

Funk MB, Notheis G, Schuster T, Elanjkal Z, von Hentig N, Stürmer M, Linde R, Dunsch D, Königs C, Wintergerst U, Kreuz W.

Eur J Med Res. 2005 Dec 7;10(12):503-8.

PMID:
16356864
2.

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM.

N Engl J Med. 1999 Dec 16;341(25):1874-81.

3.

Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.

Funk MB, Linde R, Wintergerst U, Notheis G, Hoffmann F, Schuster T, Kornhuber B, Ahrens P, Kreuz W.

AIDS. 1999 Sep 10;13(13):1653-8.

PMID:
10509566
4.

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.

Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD.

AIDS. 1999 Jul 30;13(11):F71-7.

PMID:
10449277
5.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
6.

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.

Friedl AC, Ledergerber B, Flepp M, Hirschel B, Telenti A, Furrer H, Bucher HC, Bernasconi E, Weber R; Swiss Cohort Study.

AIDS. 2001 Sep 28;15(14):1793-800.

PMID:
11579241
7.

Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.

de Truchis P, Force G, Welker Y, Mechali D, Pulik M, Chemlal K, Rouveix E, Devidas A, Praindhui D, Mamet JP; CNAF3008 Group.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):178-82.

PMID:
12394796
8.

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.

Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6.

PMID:
15980689
9.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.

Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.

AIDS. 2007 Apr 23;21(7):813-23.

PMID:
17415036
10.
11.

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group.

Clin Infect Dis. 2008 May 15;46(10):1601-8. doi: 10.1086/587657.

13.

Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children.

Engelhorn C, Hoffmann F, Notheis G, Funk M, Eberle J, Belohradsky BH, Wintergerst U.

Eur J Med Res. 2002 Jan 29;7(1):30-4.

PMID:
11827838
14.

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.

Seminari E, Maggiolo F, Villani P, Suter F, Pan A, Regazzi MB, Paolucci S, Baldanti F, Tinelli C, Maserati R.

J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):453-60. Erratum in: J Acquir Immune Defic Syndr 2000 Mar 1;23(3):278.

PMID:
10961606
15.

Delavirdine: a review of its use in HIV infection.

Scott LJ, Perry CM.

Drugs. 2000 Dec;60(6):1411-44. Review.

PMID:
11152019
16.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team.

N Engl J Med. 2001 Aug 9;345(6):398-407.

17.

Efavirenz.

Adkins JC, Noble S.

Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6. Review.

PMID:
9878993
18.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60.

PMID:
9732070
19.

Switch to efavirenz in a protease inhibitor-containing regimen.

Knechten H, Stürner KH, Höhn C, Braun P.

HIV Clin Trials. 2001 May-Jun;2(3):200-4.

PMID:
11590528
20.

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.

Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, Negredo E, Romeu J, Sirera G, Tural C, Clotet B.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):244-53.

PMID:
11873073
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk